Optimi Health Announces DTC Eligibility & Up-List to OTCQB
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its US-based OTC Markets listing under the symbol “OPTHF” has received approval from the Depository Trust Company (“DTC”) to make the Company’s common shares eligible to be electronically cleared and settled through DTC (“DTC Eligibility”).
DTC is a subsidiary of the Depository Trust and Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly traded companies. DTC Eligibility incorporates an electronic method of clearing securities that speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors. DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission.
Optimi further advises that it is nearing completion of the process to up-list to the OTCQB exchange operated by OTC Markets Group Inc. Designed for developing and entrepreneurial companies in the United States and abroad, companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities.
In addition to trading in the United States, Optimi’s common shares continue to trade on the Canadian Securities Exchange under OPTI and the German Börse Frankfurt (FRA) exchange under 8BN.
Michael Stier, CEO of Optimi notes, “Today’s news is an important milestone towards broadening our market presence across the United States as we engage with this significant shareholder audience. Listing on the OTCQB will provide heightened transparency and visibility to the investment community. DTC eligibility allows current and prospective shareholders of Optimi a reliable, cost-efficient, and timely method for clearing and settlement of our common shares. Overall, today’s news positions Optimi to engage with confidence, purpose and consideration more meaningfully with current and future investors.”
On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier
President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
